Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a massive data registry crack the code of Parkinson's and related brain diseases?

NCT ID NCT04472130

Knowledge-focused Sponsor: Vincent Mok Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 18, 2026 · Last updated Sep 18, 2026

Summary

Researchers are building a large database of cognitive, behavioral, lifestyle, and genetic information from people with neurodegenerative diseases such as Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. The goal is to find biomarkers that help doctors tell these overlapping conditions apart, especially in early stages when symptoms and brain changes look similar. The study enrolls up to 1,400 participants aged 18 to 80 and tracks their scores on standard rating scales for movement and thinking over time. This observational registry does not test a treatment; it gathers data to improve diagnosis and guide future drug trials.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the registry identifies reliable biomarkers, doctors could diagnose Parkinson's disease, multiple system atrophy, and related conditions earlier and more accurately, which may help match patients to the right treatments sooner.
What could go wrong
This is an observational registry, not a treatment trial, so it will not directly cure or slow any disease. The value depends on whether the collected data yield clear biomarker patterns, which may take years to confirm and may not translate into better patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2019

Expected to finish

Aug 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Subjects will be recruited in neurology outpatient clinic in Prince of Wales Hospital, Hong Kong, who meet the inclusion and exclusion criteria listed above.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age should be between 18-80 years old. Exclusion Criteria: * Patients with ongoing central nervous system infection and/or acute stroke or active brain tumor.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease corticobasal degeneration disorder frontotemporal dementia Lewy body dementia motor neuron disorder multiple system atrophy neurodegenerative disease Parkinson disease progressive supranuclear palsy vascular dementia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple system atrophy Neurodegenerative diseases Parkinson disease Progressive supranuclear palsy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chinese University of Hong Kong

    RECRUITING

    Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.